Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Watson Pulls Prochieve From Guidance, But Pushes For Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite a disappointing advisory committee review for its progesterone gel for preterm birth, Watson said it will continue to push for approval. The company also bolsters its Australian generics business with the acquisition of Ascent.

You may also be interested in...

Regulatory News, In Brief

Compounding remains in the news as FDA issues a ‘483 report for the compounding pharmacy behind the fungal meningitis outbreak and as KV Pharmaceuticals tries to block importation of compounded versions of Makena. Other regulatory developments include a settlement over Boehringer’s off-label promotion and a further setback for Watson’s Prochieve.

Watson May Bypass Progesterone Gel 8% For Second-Generation Product

The extent of additional clinical work required pursuant to an FDA “complete response” letter will have to be balanced against the remaining patent life on the product, for which Watson was seeking an indication to prevent preterm birth in women with a short cervix.

Watson Hopes Accelerated Approval For Progesterone Gel Remains Option

Company will meet with FDA to determine a path forward now that the agency has issued a “complete response” letter for progesterone vaginal gel 8% for reducing the risk of preterm birth in women with a short cervix, Watson CEO Bisaro says.

Related Content

Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts